Macrophage dysregulation in medication-related osteonecrosis of the jaw: jaw-specific osteoimmune mechanisms and therapeutic perspectives
- 1College of Stomatology of Guizhou Medical University
- 2Key Laboratory of Oral Disease Research, Guizhou Medical University
- 3Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Guizhou Medical University
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory complication of antiresorptive and antiangiogenic therapies. Its jaw-specific susceptibility and persistent inflammatory features are not fully explained by traditional hypotheses centered on suppressed bone remodeling or impaired angiogenesis. From an osteoimmunological perspective, this review proposes that MRONJ may be more accurately understood as an immune-mediated failure of healing within a jaw-specific osteoimmune niche, in which pathological macrophage reprogramming arises from the interplay between pharmacological exposure and the local microenvironment. Mechanistically, nitrogen-containing bisphosphonates inhibit the mevalonate pathway and disrupt the isoprenylation of small GTPases, including Rac1 and RhoA, resulting in cytoskeletal dysfunction that may impair macrophage efferocytosis. Consequently, persistent necrotic and apoptotic debris may provide ongoing danger signals that sustain NLRP3 inflammasome activation in susceptible lesions, thereby disrupting reparative coupling among bone, vasculature, and mucosa. In parallel, the unique jaw microenvironment, characterized by high local drug accumulation, biofilm colonization, and hypoxia, creates a high-burden inflammatory niche that further impairs the macrophage clearance–resolution program. Finally, this review highlights potential translational strategies, including metabolic rescue, specialized pro-resolving mediators (SPMs), and targeted local delivery of immunomodulatory biomaterials. Together, these approaches support a therapeutic roadmap centered on inflammation resolution and mucosal sealing as key clinical endpoints.
Related
- Macrophage senescence and senescence-like states in senile osteoporosis: cellular cross-talk and therapeutic perspectives
- Emerging therapeutic strategies for medication-related osteonecrosis of the jaw: From microenvironmental modulation to precision medicine (Review).
- Germinal center and extrafollicular dysregulation in systemic lupus erythematosus: Mechanisms and therapeutic opportunities
- Redox Dysregulation in the Abdominal Aortic Aneurysm Wall: Ferroptosis and Experimental Therapeutic Opportunities
- Integrated Transcriptomic Analysis Identifies a Ferroptosis-Related Gene Signature Underlying Macrophage Heterogeneity and Immune Dysregulation in Rheumatoid Arthritis Synovium
BibTeX
@article{wang2026macrophage,
title = {{Macrophage dysregulation in medication-related osteonecrosis of the jaw: jaw-specific osteoimmune mechanisms and therapeutic perspectives}},
author = {Quan Wang and Shensui Li and Changfeng Linghu and Weijun Zhou and Zhenglong Tang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1884353},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1884353/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Macrophage dysregulation in medication-related osteonecrosis of the jaw: jaw-specific osteoimmune mechanisms and therapeutic perspectives
AU - Quan Wang
AU - Shensui Li
AU - Changfeng Linghu
AU - Weijun Zhou
AU - Zhenglong Tang
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1884353
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1884353/full
AB - Medication-related osteonecrosis of the jaw (MRONJ) is a refractory complication of antiresorptive and antiangiogenic therapies. Its jaw-specific susceptibility and persistent inflammatory features are not fully explained by traditional hypotheses centered on suppressed bone remodeling or impaired angiogenesis. From an osteoimmunological perspective, this review proposes that MRONJ may be more accurately understood as an immune-mediated failure of healing within a jaw-specific osteoimmune niche, in which pathological macrophage reprogramming arises from the interplay between pharmacological exposure and the local microenvironment. Mechanistically, nitrogen-containing bisphosphonates inhibit the mevalonate pathway and disrupt the isoprenylation of small GTPases, including Rac1 and RhoA, resulting in cytoskeletal dysfunction that may impair macrophage efferocytosis. Consequently, persistent necrotic and apoptotic debris may provide ongoing danger signals that sustain NLRP3 inflammasome activation in susceptible lesions, thereby disrupting reparative coupling among bone, vasculature, and mucosa. In parallel, the unique jaw microenvironment, characterized by high local drug accumulation, biofilm colonization, and hypoxia, creates a high-burden inflammatory niche that further impairs the macrophage clearance–resolution program. Finally, this review highlights potential translational strategies, including metabolic rescue, specialized pro-resolving mediators (SPMs), and targeted local delivery of immunomodulatory biomaterials. Together, these approaches support a therapeutic roadmap centered on inflammation resolution and mucosal sealing as key clinical endpoints.
SN - 1664-3224
ER -